{"title":"Interactions of FGFs with target cells","authors":"Dominique Ledoux, Leila Gannoun-Zaki, Denis Barritault","doi":"10.1016/0955-2235(92)90026-E","DOIUrl":"10.1016/0955-2235(92)90026-E","url":null,"abstract":"<div><p>Growth factors play a key role in cellular communication, a necessary step for the development of pluricellular organisms. The fibroblast growth factors (FGF) are among these polypeptides and have seven known members: FGF 1 to FGF 7 which are also known as acidic FGF, basic FGF, translation products of oncogenes <em>hst, int 2</em>, FGF 5, FGF 6 and FGF 7 or keratinocyte growth factor (KGF) respectively[1]. <span><sup>†</sup></span> The best known and the most abundant in normal adult tissues are acidic and basic FGFs, or FGF 1 and 2 respectively, which have been subjected to extensive studies both <em>in vitro</em> and <em>in vivo</em>. These two factors have almost ubiquitous distribution and a wide spectrum of biological activity including action on cellular proliferation and differentiation, as well as neurotrophic and angiogenic properties[1]. These different activities are induced by triggering specific receptors present at the surface of the target cell. Following this interaction, the FGF-receptor complexes are internalized and activate intracellular pathways. An important effort of investigations has been produced to characterize these receptors and intracellular pathways. It is the purpose of this review to present this work which will focus on FGFs 1 and 2. The existence of two classes of interactions has been reported as early as 1987 [52,53,54] suggesting the presence of high and low affinity receptors for FGFs.</p></div>","PeriodicalId":77335,"journal":{"name":"Progress in growth factor research","volume":"4 2","pages":"Pages 107-120"},"PeriodicalIF":0.0,"publicationDate":"1992-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0955-2235(92)90026-E","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12473393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Interleukin-11: A novel stroma-derived cytokine","authors":"Ichiro Kawashima, Yo Takiguchi","doi":"10.1016/0955-2235(92)90019-E","DOIUrl":"10.1016/0955-2235(92)90019-E","url":null,"abstract":"<div><p>Interleukin-11 (IL-11) is a novel stroma-derived cytokine that acts on both hematopoietic progenitors and stromal cells. IL-11 was originally identified in a medium conditioned by the macaque bone marrow-derived stromal cell line PU-34 and cloned as a growth factor for the IL-6-dependent plasmacytoma cell line T1165. IL-11 stimulates T-cell dependent development of antibody-producing B cells and is synergistic with IL-3 to stimulate megakaryocyte colony formation. Adipogenesis inhibitory factor (AGIF) was cloned from the human bone marrow-derived stromal cell line KM-102. The AGIF cDNA sequence was revealed to be identical to that of the IL-11 cDNA. AGIF inhibits the process of adipogenesis of the bone marrow-derived preadipocyte cell line <span><math><mtext>H-1</mtext><mtext>A</mtext></math></span>. Other biological activities such as stimulation of stem-cell proliferation, erythropoiesis, lymphohematopoiesis and hepatic acute-phase response are also summarized. The human IL-11 gene consists of five exons and four introns, and was mapped on chromosome 19 at band 19q13.3-q13.4. A single class of high-affinity IL-11 receptor (IL-11R) of 151 kDa is present on 3T3-L1 preadipocytes. A protein-tyrosine kinase pathway may be involved in the initiation of the IL-11R-mediated signal transduction.</p></div>","PeriodicalId":77335,"journal":{"name":"Progress in growth factor research","volume":"4 3","pages":"Pages 191-206"},"PeriodicalIF":0.0,"publicationDate":"1992-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0955-2235(92)90019-E","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12481696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Leukemia inhibitory factor (LIF): A growth factor with pleiotropic effects on bone biology","authors":"Peter Van Vlasselaer","doi":"10.1016/0955-2235(92)90015-A","DOIUrl":"10.1016/0955-2235(92)90015-A","url":null,"abstract":"<div><p>Historically, growth factors are denominated based on a specific biological activity. In many cases, these factors display a much broader spectrum of activities, especially when their effect is tested on various cell or tissue types. Consequently, names of certain factors are quite deceptive. A textbook example is leukemia inhibitory factor (LIF). LIF was initially described based on its ability to induce differentiation in the murine myeloid leukemia cell line M1. Later, LIF turned out to be a synonym for at least nine different factors defined on the basis of their effects on a variety of cell types including lymphomas, liver cells, embryonic stem cells and carcinoma cells, neurons, melanomas and osteoclasts. Apart from its differential effect on unrelated cell types and tissues, LIF induces biphasic effects on cells of the same “lineage” as well. Needless to say, LIF activity in these circumstances largely depends on the developmental stage of the target cells. An example is LIF activity on bone cells. Osteoclast as well as osteoblast activity is stimulated or suppressed by LIF depending on the developmental stage of the respective cells. This concept is of utmost importance in the evaluation of the seemingly opposing or contradictory effects of LIF <em>in vitro</em> as well as <em>in vivo</em>.</p></div>","PeriodicalId":77335,"journal":{"name":"Progress in growth factor research","volume":"4 4","pages":"Pages 337-353"},"PeriodicalIF":0.0,"publicationDate":"1992-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0955-2235(92)90015-A","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12513028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Clinical applications of interleukin-2","authors":"A. von Rohr , N. Thatcher","doi":"10.1016/0955-2235(92)90021-9","DOIUrl":"10.1016/0955-2235(92)90021-9","url":null,"abstract":"<div><p>Interleukin-2 (IL-2) is a cytokine with potent immunomodulating properties which has shown considerable antitumour activity in preclinical models. In clinical trials, the effects of IL-2 given by various routes and schedules have been investigated. IL-2 has been administered either as single drug or in combination with other cytokines and immunomodulating agents, chemo therapeutic agents, or reinfusions of <em>ex vivo</em> activated autologous cytotoxic effector cells. The results of published clinical studies with IL-2 based immunotherapy are reviewed in this paper.</p></div>","PeriodicalId":77335,"journal":{"name":"Progress in growth factor research","volume":"4 3","pages":"Pages 229-246"},"PeriodicalIF":0.0,"publicationDate":"1992-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0955-2235(92)90021-9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12481698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Juha Partanen , Satu Vainikka , Jaana Korhonen , Elina Armstrong , Kari Alitalo
{"title":"Diverse receptors for fibroblast growth factors","authors":"Juha Partanen , Satu Vainikka , Jaana Korhonen , Elina Armstrong , Kari Alitalo","doi":"10.1016/0955-2235(92)90005-3","DOIUrl":"10.1016/0955-2235(92)90005-3","url":null,"abstract":"<div><p>The development and maintenance of multicellular organisms requires a complex interplay between cells in different tissues. Many of the factors mediating cell-cell communication are polypeptides, which were originally identified because of their ability to stimulate cell growth. In addition to growth signalling several of these factors have been observed to modulate cell survival, chemotaxis and differentiation both <em>in vitro</em> and <em>in vivo</em>. Fibroblast growth factors are a good example of polypeptide mitogens eliciting a wide variety of responses depending on the target cell type. Our knowledge of the cell surface receptors mediating the effects of FGFs has recently expanded remarkably. Perhaps not surprisingly, the complexity of the FGF family and FGF induced responses is reflected as diversity and redundancy of the FGF receptors.</p></div>","PeriodicalId":77335,"journal":{"name":"Progress in growth factor research","volume":"4 1","pages":"Pages 69-83"},"PeriodicalIF":0.0,"publicationDate":"1992-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0955-2235(92)90005-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12499167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Ciliary neurotrophic factor and its receptor complex","authors":"Nancy Y. Ip, George D. Yancopoulos","doi":"10.1016/0955-2235(92)90028-G","DOIUrl":"10.1016/0955-2235(92)90028-G","url":null,"abstract":"<div><p>Ciliary neurotrophic factor (CNTF), originally identified for its ability to promote survival of neurons of the ciliary ganglion, is now known to have additional survival and differentiative actions on cells of the nervous system. CNTF is, however, unrelated in structure to the nerve growth factor family of neurotrophic factors. Instead, CNTF is distantly related to, and in fact shares receptor components with, a number of hemopoietic cytokines. This review focuses on the biological actions of CNTF, the shared and unique features of the CNTF receptor complex and signaling pathways, and the distribution of CNTF and its receptor during development, in the adult and in response to injury.</p></div>","PeriodicalId":77335,"journal":{"name":"Progress in growth factor research","volume":"4 2","pages":"Pages 139-155"},"PeriodicalIF":0.0,"publicationDate":"1992-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0955-2235(92)90028-G","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12512795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"In vivo interactions of TGF-β and extracellular matrix","authors":"Nancy A. Noble , John R. Harper , Wayne A. Border","doi":"10.1016/0955-2235(92)90017-C","DOIUrl":"10.1016/0955-2235(92)90017-C","url":null,"abstract":"<div><p>TGF-β, a multifunctional cytokine, plays an important role in embryogenesis and in regulating repair and remodeling following tissue injury. Many of the biological actions of TGF-β are mediated by widespread effects on deposition of extracellular matrix. TGF-β stimulates the synthesis of individual matrix components including proteoglycans, collagens and glycoproteins. TGF-β also blocks matrix degradation by decreasing the synthesis of proteases and increasing the synthesis of protease inhibitors. Finally, TGF-β increases the synthesis of matrix receptors and alters their relative proportions on the surface of cells in a manner that could facilitate adhesion to matrix. All of these events have largely been demonstrated <em>in vitro</em> in cultured cells. In an experimental model of glomerulonephritis we have shown that TGF-β is responsible for the accumulation of pathological matrix in the glomeruli following immunological injury. Furthermore, all three of TGF-β's actions on extracellular matrix—increased synthesis, decreased degradation and modulation of receptors—have now been documented to be involved in matrix deposition <em>in vivo</em> in this model. Administration of the proteoglycan decorin suppressed TGF-β-induced matrix deposition in the nephritic glomeruli, thus confirming a physiological role for decorin as a regulator of TGF-β. Inhibitors of TGF-β may be important future drugs in treating fibrotic diseases caused by overproduction of TGF-β.</p></div>","PeriodicalId":77335,"journal":{"name":"Progress in growth factor research","volume":"4 4","pages":"Pages 369-382"},"PeriodicalIF":0.0,"publicationDate":"1992-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0955-2235(92)90017-C","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12514368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A.Gregory Bruce , Peter S. Linsley , Timothy M. Rose
{"title":"Oncostatin M","authors":"A.Gregory Bruce , Peter S. Linsley , Timothy M. Rose","doi":"10.1016/0955-2235(92)90029-H","DOIUrl":"10.1016/0955-2235(92)90029-H","url":null,"abstract":"<div><p>Oncostatin M (OSM) was initially identified as a polypeptide cytokine which inhibited the <em>in vitro</em> growth of cells from melanoma and other solid tumors. OSM shows significant similarities in primary amino acid sequence and predicted secondary structure to leukemia inhibitory factor (LIF), ciliary neurotrophic factor (CNTF), granulocyte colony-stimulating factor (G-CSF), interleukin 6 (IL-6), and interleukin 11 (IL-11). Analysis of the genes encoding these proteins reveals a shared exon organization suggesting evolutionary descent from a common ancestral gene. Recent data indicates that OSM also shares a number of <em>in vitro</em> activities with other members of this cytokine family. The overlapping biological effects appear to be explained by the sharing of receptor subunits.</p></div>","PeriodicalId":77335,"journal":{"name":"Progress in growth factor research","volume":"4 2","pages":"Pages 157-170"},"PeriodicalIF":0.0,"publicationDate":"1992-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0955-2235(92)90029-H","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12512796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
